Alligator Bioscience announced the completion of patient enrolment in the ongoing OPTIMIZE-1 Phase 2 trial of the company's lead asset mitazalimab in 1st line metastatic pancreatic cancer. Thanks to this acceleration in patient enrolment, Alligator confirms it expects to report top-line data in the beginning of First Quarter 2024. The open-label, multi-center study is assessing the safety and efficacy of mitazalimab (CD40 mAb) in combination with chemotherapy, mFOLFIRINOX, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma.